Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease

May combine two claims.

The PSEN1E280A mutation causes autosomal dominant Alzheimer's disease with predictable onset.

“The PSEN1E280A mutation causes autosomal dominant Alzheimer's disease (ADAD) with predictable onset, enabling presymptomatic studies.”

• cites [3] Quiroz YT, Aguillon D, Aguirre‐Acevedo DC, et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's Disease. N Engl J Med. 2024; 390(23): 2156‐ 2164. 38899694 PMC12640232 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE3Ch carriers are known to have hyperlipoproteinemia.

“APOE3Ch carriers are known to have hyperlipoproteinemia 5 though it is unknown whether they have differences in the EVs properties and functional roles.”

• cites [5] Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; 25(11): 1680‐ 1683. 31686034 PMC6898984 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

EVs are nanoscale lipid bilayer-enclosed structures secreted by cells that carry proteins, lipids, and nucleic acids.

“EVs are nanoscale lipid bilayer‐enclosed structures secreted by cells that carry proteins, lipids, and nucleic acids. 19”

• cites [19] Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13(2): e12404. 38326288 PMC10850029 sourcePartly supported

  The Nomenclature section defines EVs as particles released from cells and delimited by a lipid bilayer. The protein-composition and nucleic-acid-characterization sections support their association with proteins and nucleic acids. However, the Quantification of particle size section says EV diameters range from tens of nanometres to microns, so describing all EVs as nanoscale is too narrow. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Peripheral biomarkers are increasingly recognized as valuable for detecting early brain changes in MCI and AD, supporting diagnostic and therapeutic strategies at preclinical stages.

“Peripheral biomarkers are increasingly recognized as valuable for detecting early brain changes in MCI and AD, supporting diagnostic and therapeutic strategies at preclinical stages. 13”

• cites [13] Klyucherev TO, Olszewski P, Shalimova AA, et al. Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener. 2022; 11(1): 25. 35449079 PMC9027827 sourceSupported

May combine two claims.

APOE3Ch displays reduced affinity for LDLR, decreasing lipid uptake and intracellular accumulation of toxic lipids.

“It also displays reduced affinity for the low‐density lipoprotein receptor (LDLR), decreasing lipid uptake and intracellular accumulation of toxic lipids, 7”

• cites [7] Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025; 188(1): 187‐ 206.e26. 39532095 PMC11724755 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

In non-demented individuals, lipid, inflammatory, and metabolic profiles predict cognitive performance and its trajectory.

“In non‐demented individuals, lipid, inflammatory, and metabolic profiles predict cognitive performance and its trajectory. 14 , 15”

• cites [14] Fiocco AJ, Krieger L, D'Amico D, et al. A systematic review of existing peripheral biomarkers of cognitive aging: is there enough evidence for biomarker proxies in behavioral modification interventions? Ageing Res Rev. 2019; 52: 72‐ 119. 31059801 sourceNot checked — no full text of the source
• cites [15] Chen J, Doyle MF, Fang Y, et al. Peripheral inflammatory biomarkers are associated with cognitive function and dementia: framingham Heart Study Offspring cohort. Aging Cell. 2023; 22(10): e13955. 37584418 PMC10577533 sourcePartly supported

  The Abstract reports associations between inflammatory proteins and cognitive-domain scores in participants who were dementia-free at baseline. The Methods treat lipid and metabolic measures as covariates, not as profiles shown to predict cognition. The Discussion says the cognitive analyses were cross-sectional, so the paper does not establish prediction of cognitive trajectory. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

EVs mediate intercellular communication and reflect the physiological or pathological state of their origin.

“They mediate intercellular communication and reflect the physiological or pathological state of their origin. 20”

• cites [20] Yáñez‐Mó M, Siljander PRM, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4: 27066. 25979354 PMC4433489 sourceSupported

May combine two claims.

NVU dysfunction is a key regulator of brain-periphery communication and is implicated in AD pathogenesis.

“As NVU dysfunction, a key regulator of brain–periphery communication, is implicated in AD pathogenesis, biomarkers capturing early NVU alterations, including those from systemic or peripheral factors, are needed.”

• cites [9] Yu X, Ji C, Shao A. Neurovascular unit dysfunction and neurodegenerative disorders. Front Neurosci. 2020; 14: 334. 32410936 PMC7201055 sourceSupported
• cites [10] Posada‐Duque RA, Cardona‐Gómez GP. CDK5 targeting as a therapy for recovering neurovascular unit integrity in Alzheimer's Disease. J Alzheimers Dis. 2020; 82(S1): S141‐ S161. 33016916 sourceNot checked — no full text of the source

May combine two claims.

Heterozygous APOE3Ch carriers showed reduced cerebral amyloid angiopathy, attenuated parenchymal vascular abnormalities, and less microvessel fragmentation compared to typical PSEN1E280A cases.

“Post mortem studies revealed that the brain of a homozygous APOE3Ch carrier exhibited minimal astrocytic and microglial activation and clear vascular protection, while heterozygous carriers showed reduced cerebral amyloid angiopathy, attenuated parenchymal vascular abnormalities, and less microvessel fragmentation compared to typical PSEN1E280A cases. 3 , 11 , 12”

• cites [3] Quiroz YT, Aguillon D, Aguirre‐Acevedo DC, et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's Disease. N Engl J Med. 2024; 390(23): 2156‐ 2164. 38899694 PMC12640232 sourcePartly supported

  The Results section, “Pathological Findings in Persons with APOE3Ch” (page unavailable), reports less prominent cerebral amyloid angiopathy in the frontal cortex of carriers and vessel length, branching, and spacing more similar to controls than to PSEN1E280A noncarriers. These findings support reduced vascular pathology, but the passage does not specifically establish less microvessel fragmentation or characterize the abnormalities as parenchymal. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [11] Henao‐Restrepo J, López‐Murillo C, Valderrama‐Carmona P, et al. Gliovascular alterations in sporadic and familial Alzheimer's disease: aPOE3 Christchurch homozygote glioprotection. Brain Pathol. 2022; 33(2): e13119. 36130084 PMC10041169 sourcePartly supported

  The Materials and Methods (Human samples; page unavailable) identify the APOE3 Christchurch carrier studied as homozygous, not heterozygous. The Discussion reports greater preservation of gliovascular structure and vascular integrity in that case, but does not establish the claimed reductions in cerebral amyloid angiopathy or microvessel fragmentation in heterozygous carriers. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [12] Sepulveda‐Falla D, Sanchez JS, Almeida MC, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022; 144: 589‐ 601. 35838824 PMC9381462 sourceCould not verify

  The Introduction and Results > Neuropathological findings describe a homozygous APOE3 Christchurch carrier, not heterozygous carriers. Searches for heterozygous carriers and microvessel fragmentation found no passage in our copy reporting the claimed vascular comparisons, so this source cannot verify that part of the citing sentence. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

APOE3Ch reduces binding to heparan sulfate proteoglycans, promoting cellular uptake and tau degradation and reducing tauopathy propagation.

“Mechanistic studies demonstrate that the APOE3Ch variant reduces binding to heparan sulfate proteoglycans (HSPGs), promoting cellular uptake and tau degradation and reducing tauopathy propagation. 5 , 6”

• cites [5] Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; 25(11): 1680‐ 1683. 31686034 PMC6898984 sourcePartly supported

  The paper reports that ApoE3ch had the lowest heparin-binding ability among the ApoE isoforms tested (Abstract; page unavailable), supporting the reduced-binding portion of the claim. It only postulates a beneficial effect on tau pathology related in part to altered HSPG affinity; it does not demonstrate that APOE3ch promotes cellular uptake or tau degradation, or reduces tauopathy propagation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [6] Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses Aβ‐induced tau seeding and spread. Cell. 2024; 187(2): 428‐ 445.e20. 38086389 PMC10842861 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Because the Christchurch variant alters lipid binding and receptor interactions, it may shape EV content in ways that confer protection.

“Because the Christchurch variant alters lipid binding and receptor interactions, key processes in lipid metabolism 7 and EV biogenesis, it may shape EV content in ways that confer protection.”

• cites [7] Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025; 188(1): 187‐ 206.e26. 39532095 PMC11724755 sourcePartly supported

  The Results section (page unavailable) shows that the Christchurch variant reduces binding of lipidated ApoE to LDLR and decreases uptake of its lipid cargoes; the Discussion links this mechanism to protection. The paper does not show that the variant alters ApoE’s binding to lipids. Shaping EV content is the citing authors’ proposed implication, not a finding established by this source. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Altered EV profiles are detectable at prodromal stages such as MCI, supporting their value as early biomarkers.

“Altered EV profiles are detectable at prodromal stages such as MCI, supporting their value as early biomarkers. 26 , 27”

• cites [26] Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case‐control study. Alzheimers Dement. 2015; 11(6): 600‐ 607.e1. 25130657 PMC4329112 sourceSupported
• cites [27] Kapogiannis D, Mustapic M, Shardell MD, et al. Association of extracellular vesicle biomarkers with Alzheimer Disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2019; 76(11): 1340‐ 1351. 31305918 PMC6632160 sourcePartly supported

  The Results report altered neuronal-enriched EV biomarkers in participants who later developed Alzheimer disease, supporting their potential as early biomarkers. But the Participants and Study Design section says samples were drawn before symptom onset; when a participant developed MCI, samples from that visit and later were excluded. This paper therefore does not establish that altered profiles were detectable at the MCI stage. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The PSEN1E280A variant causes an aggressive form of ADAD, with carriers typically developing cognitive decline before age 47.

“Among these, the PSEN1E280A variant causes an aggressive form of ADAD, with carriers typically developing cognitive decline before age 47. 3”

• cites [3] Quiroz YT, Aguillon D, Aguirre‐Acevedo DC, et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's Disease. N Engl J Med. 2024; 390(23): 2156‐ 2164. 38899694 PMC12640232 sourcePartly supported

  The introductory passage following the Abstract says that autosomal dominant Alzheimer’s disease is nearly certain to develop in PSEN1E280A carriers and that most have mild cognitive impairment in their mid-forties. The Results report a median onset of approximately 47 years in matched carriers without APOE3 Christchurch, not an onset before 47; the claim’s precise age cutoff is therefore not established. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

NVU integrity depends on endothelial cells, astrocytes, microglia, and mural cells, and its dysfunction contributes to AD pathogenesis.

“These mechanisms are closely linked to neurovascular unit (NVU) integrity, which depends on endothelial cells, astrocytes, microglia, and mural cells, and whose dysfunction contributes to AD pathogenesis. 9 , 10”

• cites [9] Yu X, Ji C, Shao A. Neurovascular unit dysfunction and neurodegenerative disorders. Front Neurosci. 2020; 14: 334. 32410936 PMC7201055 sourceSupported
• cites [10] Posada‐Duque RA, Cardona‐Gómez GP. CDK5 targeting as a therapy for recovering neurovascular unit integrity in Alzheimer's Disease. J Alzheimers Dis. 2020; 82(S1): S141‐ S161. 33016916 sourceNot checked — no full text of the source

The quote only partly states this claim.

Neuroimaging data revealed relatively preserved cortical structure with low tau accumulation in regions typically affected by early neurodegeneration in APOE3Ch carriers.

“Neuroimaging data further revealed relatively preserved cortical structure with low tau accumulation in regions typically affected by early neurodegeneration. 3”

• cites [3] Quiroz YT, Aguillon D, Aguirre‐Acevedo DC, et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's Disease. N Engl J Med. 2024; 390(23): 2156‐ 2164. 38899694 PMC12640232 sourcePartly supported

  The Results section (page not provided) reports a more limited tau burden in Alzheimer’s-related regions, including the entorhinal cortex, on PET imaging of one APOE3Ch heterozygote. It reports relatively preserved glucose metabolism in the imaged participants, not relatively preserved cortical structure. Structural MRI was performed, but the cited passages do not report a finding of preserved cortical structure. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

In the Paisa kindred, plasma alterations such as elevated Aβ1-42, altered Aβ1-42/Aβ1-40 ratios, and increased p-tau217 appear before clinical symptom onset.

“In the Paisa kindred, plasma alterations such as elevated amyloid beta (Aβ)1‐42, altered Aβ1‐42/Aβ1‐40 ratios, and increased tau phosphorylated at threonine 217 (p‐tau217) appear before clinical symptom onset. 16 , 17”

• cites [16] Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross‐sectional study. JAMA Neurol. 2015; 72(3): 316‐ 324. 25580592 PMC4355261 sourcePartly supported

  The Results (CSF and Plasma Biomarkers; page unavailable) report higher plasma Aβ1-42 in mutation carriers than noncarriers, and the Discussion says this was also true in cognitively unimpaired carriers. The paper does not report an altered plasma Aβ1-42/Aβ1-40 ratio or measure plasma p-tau217; its phosphorylated-tau findings concern CSF p-tau181. It also found no age-associated change in plasma Aβ1-42, so it does not establish when that plasma difference first appears. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [17] Aguillon D, Langella S, Chen Y, et al. Plasma p‐tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023; 19(6): 2585‐ 2594. 36571821 PMC10271963 sourcePartly supported

  The Discussion reports higher plasma p-tau217 in PSEN1 E280A carriers than in non-carriers before cognitive impairment. The paper does not report presymptomatic elevations in plasma Aβ1-42 or altered plasma Aβ1-42/Aβ1-40 ratios; its amyloid findings concern brain PET measurements, not those plasma markers (Results, “Group differences in biomarkers at follow-up assessment”). (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

In AD, EVs contribute to tau propagation, neuroinflammatory signaling, astrocyte activation, and vascular dysfunction.

“In AD, EVs contribute to tau propagation, neuroinflammatory signaling, astrocyte activation, and vascular dysfunction. 21 , 22 , 23 , 24 , 25”

• cites [21] Ruan Z, Pathak D, Venkatesan Kalavai S, et al. Alzheimer's disease brain‐derived extracellular vesicles spread tau pathology in interneurons. Brain. 2020; 144(1): 288‐ 309. PMC7880668 33246331 sourcePartly supported

  The Discussion reports that Alzheimer’s disease EVs initiate tau propagation in mice. Its discussion of inflammation describes inflammatory conditions affecting EV composition and uptake, not EVs causing neuroinflammatory signaling. The cited passages do not establish that EVs activate astrocytes or cause vascular dysfunction; page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [22] Crotti A, Sait HR, McAvoy KM, et al. BIN1 favors the spreading of Tau via extracellular vesicles. Sci Rep. 2019; 9: 9477. 31263146 PMC6603165 sourcePartly supported

  The Discussion reports seeding-competent, Tau-containing EVs from the CSF of people with AD and findings consistent with EV-mediated Tau spreading. The paper does not establish the other effects attributed to EVs in the sentence: neuroinflammatory signaling, astrocyte activation, or vascular dysfunction. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [23] Delpech JC, Herron S, Botros MB, Ikezu T. Neuroimmune crosstalk through extracellular vesicles in health and disease. Trends Neurosci. 2019; 42(5): 361‐ 372. 30926143 PMC6486849 sourcePartly supported

  The EV Crosstalk in CNS Disease section links EVs in AD to tau propagation and neuroinflammation. Neuroimmune Communication with EVs reports astrocyte activation by microglial EVs in rodent experiments, but does not establish that effect specifically in AD. The passages found do not link EVs to vascular dysfunction in AD; the indexed copy provides no page numbers. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Systemic extracellular vesicles interact directly with endothelial cells and can cross the blood-brain barrier to reach the brain parenchyma.

“We demonstrated that systemic EVs interact directly with endothelial cells and can cross the blood–brain barrier (BBB) to reach the brain parenchyma. 24”

• cites [24] Villar‐Vesga J, Henao‐Restrepo J, Voshart DC, et al. Differential profile of systemic extracellular vesicles from sporadic and familial Alzheimer's Disease leads to neuroglial and endothelial cell degeneration. Front Aging Neurosci. 2020; 12(587989): 587989. 33281599 PMC7705379 sourcePartly supported

  The Results section reports that systemic EVs crossed a human brain microvasculature cell layer and affected endothelial cells; the Discussion says AD-EVs interacted with neurovascular-unit cells. But the BBB-crossing test was an in vitro model, so the paper does not demonstrate that the EVs reached brain parenchyma in vivo. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

ApoE, mainly a plasma lipoprotein component, can also exist in non-lipidated form and within EVs.

“ApoE, mainly a plasma lipoprotein component, 55 can also exist in non‐lipidated form and within EVs. 56 , 57”

• cites [55] Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis. 2014; 72: 3‐ 12. 25173806 PMC4253862 sourceSupported
• cites [56] Jiang S, Li X, Li Y, et al. APOE from patient‐derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model. Sci Transl Med. 2025; 16(736): eadg5116. 38416841 sourcePartly supported

  The paper’s title, reproduced in the indexed Abstract record, identifies APOE in patient-derived astrocytic extracellular vesicles, supporting the EV portion of the claim. The supplied passages and searches for non-lipidated APOE do not establish that form. The plasma-lipoprotein clause has a separate citation (55) and is not assessed here. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [57] Nikitidou E, Khoonsari PE, Shevchenko G, Ingelsson M, Kultima K, Erlandsson A. Increased release of apolipoprotein e in extracellular vesicles following amyloid‐β protofibril exposure of neuroglial co‐cultures. J Alzheimers Dis. 2017; 60(1): 305‐ 321. 28826183 PMC5676865 sourcePartly supported

  The Results section ('Apolipoprotein E is primarily situated inside isolated EVs'; page unavailable) confirms that apoE can occur within extracellular vesicles. The paper does not establish that apoE can exist in non-lipidated form; its observation of some apoE outside intact EVs does not determine whether that apoE is lipidated. The plasma-lipoprotein description is attached to a different citation in the citing sentence. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

Classical biomarkers such as cerebrospinal fluid and plasma define disease staging decades before onset but mainly reflect downstream protein pathology.

“Classical biomarkers such as cerebrospinal fluid (CSF) and plasma define disease staging decades before onset but mainly reflect downstream protein pathology. 42”

• cites [42] Fuller JT, Cronin‐Golomb A, Gatchel JR, et al. Biological and Cognitive markers of presenilin1 E280A s. J Prev Alzheimers Dis. 2019; 6(2): 112‐ 120. 30756118 PMC6925534 sourcePartly supported

  The Results section (‘Plasma, CSF, and other in vivo markers of AD pathology’; page unavailable) reports CSF and plasma amyloid abnormalities decades before symptoms in PSEN1 E280A carriers. The Discussion describes a suggested temporal order modeled from cross-sectional findings, not definitive disease staging. The paper identifies these as markers of AD pathology but does not characterize them as mainly reflecting downstream protein pathology. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Evidence supports a protective role for APOE3Ch: homozygous carriers showed reversal of cerebral hypometabolism, and heterozygotes exhibited reduced angiogenesis and cerebral amyloid angiopathy.

“Despite broader age variability, evidence supports a protective role for APOE3Ch : homozygous carriers showed reversal of cerebral hypometabolism, 5 and heterozygotes exhibited reduced angiogenesis and cerebral amyloid angiopathy. 3”

• cites [5] Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; 25(11): 1680‐ 1683. 31686034 PMC6898984 sourceCould not verify

  Citation 3 is attached to the claim about heterozygotes. The paper’s Methods (APOE Genotyping by Sanger sequencing; page unavailable) identifies heterozygous descendants, but the passages found do not report reduced angiogenesis or cerebral amyloid angiopathy in them. Searches for those outcomes found no supporting passage. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [3] Quiroz YT, Aguillon D, Aguirre‐Acevedo DC, et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's Disease. N Engl J Med. 2024; 390(23): 2156‐ 2164. 38899694 PMC12640232 sourcePartly supported

  Citation 3 is attached to the claim about heterozygotes. The Results section, under “Pathological Findings in Persons with APOE3Ch” (page unavailable), reports less prominent cerebral amyloid angiopathy in APOE3Ch carriers than in noncarriers. It describes vessel shape and spacing but does not report reduced angiogenesis. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Prior observations in isogenic iPSC-derived brain organoids showed that APOE3Ch variant enhanced Wnt3a signaling and increased expression of β-catenin target genes, despite reduced levels of Wnt ligands.

“These findings are consistent with prior observations in isogenic induced pluripotent stem cell (iPSC)‐derived brain organoids, where the APOE3Ch variant enhanced Wnt3a signaling and increased expression of β‐catenin target genes, despite exhibiting reduced levels of Wnt ligands. 8”

• cites [8] Perez‐Corredor P, Vanderleest TE, Vacano GN, et al. APOE3 Christchurch modulates β‐catenin/Wnt signaling in iPS cell‐derived cerebral organoids from Alzheimer's cases. Front Mol Neurosci. 2024; 17: 1373568. 38571814 PMC10987717 sourcePartly supported

  The Results sections on Wnt3a signaling and single-cell RNA sequencing report that ApoE3Ch enhanced Wnt3a-dependent signaling in a HEK293 reporter assay, while APOE3Ch organoids had reduced Wnt-ligand transcripts and increased β-catenin protein. Our copy does not report increased expression of β-catenin target genes in the organoids; the Wnt3a enhancement was tested in reporter cells, not directly in the organoids. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

In APOE3Ch, IPA analysis indicated activation of anti-angiogenic IL-12 signaling and predicted inactivation of IL-6.

“In APOE3Ch , IPA analysis indicated activation of anti‐angiogenic IL‐12 signaling, 47 along with predicted inactivation of IL‐6, an upstream regulator associated with inflammation, vascular activation, and coagulation. 48”

• cites [47] Mitola S, Strasly M, Prato M, Ghia P, Bussolino F. IL‐12 regulates an endothelial cell‐lymphocyte network: effect on metalloproteinase‐9 production. J Immunol. 2003; 171(7): 3725‐ 3733. 14500672 sourceSupported
• cites [48] Villar‐Fincheira P, Sanhueza‐Olivares F, Norambuena‐Soto I, et al. Role of interleukin‐6 in vascular health and disease. Front Mol Biosci. 2021; 8: 641734. 33786327 PMC8004548 sourceSupported

Classified as probably not a substantial claim.

Platelet EVs can carry regulatory and pro-neurogenic factors.

“Given that platelet EVs can also carry regulatory and pro‐neurogenic factors, 50 , 51 , 52 this profile may reflect an altered platelet state favoring vesicle‐mediated communication over thrombosis.”

• cites [50] Oggero S, Austin‐Williams S, Norling LV. The contrasting role of extracellular vesicles in vascular inflammation and tissue repair. Front Pharmacol. 2019; 10: 1479. 31920664 PMC6928593 sourcePartly supported

  The “Extracellular Vesicles in Vascular Inflammation” section reports that platelet-derived EVs carry growth factors and other components with immunomodulatory effects. The “EVs in Tissue Resolution and Repair” section discusses neurogenesis, but attributes it to mesenchymal stem cell-derived EVs, not platelet EVs. This source therefore supports regulatory cargo but not the pro-neurogenic part of the claim. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [51] Burnouf T, Walker TL. The multifaceted role of platelets in mediating brain function. Blood. 2022; 140(8): 815‐ 827. 35609283 PMC9412009 sourceSupported
• cites [52] Leiter O, Walker TL. Platelets: the missing link between the blood and brain? Prog Neurobiol. 2019; 183: 101695. 31550515 sourceSupported

May combine two claims.

Post mortem studies showed preserved astrocytic architecture in APOE3Ch, and astrocyte-derived EVs exhibited reduced AQP4, consistent with maintained BBB integrity.

“Post mortem studies showed preserved astrocytic architecture in APOE3Ch , 11 and astrocyte‐derived EVs exhibited reduced AQP4, consistent with maintained BBB integrity. 49”

• cites [11] Henao‐Restrepo J, López‐Murillo C, Valderrama‐Carmona P, et al. Gliovascular alterations in sporadic and familial Alzheimer's disease: aPOE3 Christchurch homozygote glioprotection. Brain Pathol. 2022; 33(2): e13119. 36130084 PMC10041169 sourceSupported
• cites [49] Nicchia GP, Nico B, Camassa LMA, et al. The role of aquaporin‐4 in the blood–brain barrier development and integrity: studies in animal and cell culture models. Neuroscience. 2004; 129(4): 935‐ 944. 15561409 sourceNot checked — no full text of the source

Classified as probably not a substantial claim. May combine two claims.

SLC4A1 regulates peripheral pH and redox buffering, and its loss has been linked to oxidative stress and neurodegeneration.

“Of note, SLC4A1 regulates peripheral pH and redox buffering, and its loss has been linked to oxidative stress and neurodegeneration, 62 , 63 suggesting that its enrichment in APOE3Ch ‐EVs may support endothelial resilience.”

• cites [62] Remigante A, Spinelli S, Pusch M, et al. Role of SLC4 and SLC26 solute carriers during oxidative stress. Acta Physiologica. 2022; 235(1): e13796. 35143116 PMC9542443 sourcePartly supported

  The SLC4A1 isoform section describes bicarbonate exchange in peripheral tissues, supporting a role in pH regulation, and reports oxidative-stress-related changes in band 3 function. Its ageing subsection reports accelerated band 3 breakdown in people with Alzheimer’s disease. It does not establish that SLC4A1 provides redox buffering or that its loss contributes to neurodegeneration. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [63] Zhong J, Dong J, Ruan W, Duan X. Potential Theranostic roles of SLC4 molecules in human diseases. Int J Mol Sci. 2023; 24(20): 15166. 37894847 PMC10606849 sourcePartly supported

  Section 4.1 says SLC4A1 regulates blood pH through chloride–bicarbonate exchange. Section 6.1 links oxidative stress to modifications of SLC4A1, but does not say SLC4A1 provides redox buffering or that its loss is linked to oxidative stress and neurodegeneration. Page numbers were not available in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Genetic inhibition of endothelial β-catenin exacerbates inflammation and barrier disruption, increasing CD4+ T cell infiltration, VCAM-1 and caveolin-1 expression, and transcytosis in autoimmune encephalomyelitis models.

“Genetic inhibition of endothelial β‐catenin exacerbates inflammation and barrier disruption, increasing CD4+ T cell infiltration, VCAM‐1 and caveolin‐1 expression, and transcytosis in autoimmune encephalomyelitis models. 67”

• cites [67] Lengfeld JE, Lutz SE, Smith JR, et al. Endothelial Wnt/β‐catenin signaling reduces immune cell infiltration in multiple sclerosis. Proc Natl Acad Sci. 2017; 114(7): E1168‐ E1177. 28137846 PMC5320985 sourceSupported

May combine two claims.

APOE3Ch may promote hyperlipidemia due to reduced receptor binding but also limit uptake of oxidized lipoproteins, protecting against lipid overload and oxidative stress.

“APOE variants contribute to lipid disorders 58 ; like APOE2, APOE3Ch may promote hyperlipidemia due to reduced receptor binding but also limit uptake of oxidized lipoproteins, protecting against lipid overload and oxidative stress. 7”

• cites [7] Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025; 188(1): 187‐ 206.e26. 39532095 PMC11724755 sourcePartly supported

  The Results section, “Christchurch mutation R136S reduces LDLR binding and decreases lipid burden” (page unavailable), reports reduced LDLR binding and uptake of ApoE and its lipid cargoes by ApoE3 Christchurch, with attenuated lipofuscinosis. It does not establish reduced uptake of already-oxidized lipoproteins: the tested cargo was peroxidation-prone PUFA-containing cholesteryl ester. The Discussion (page unavailable) also associates the Christchurch variant with lower LDL or ApoB levels, contrary to the suggested hyperlipidemia. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Recent work identified inflammatory signatures in APOE ε4/ε4 across brain, CSF, and plasma using high-powered cohorts.

“This is underscored by recent work, which identified inflammatory signatures in APOE ε4/ε4 across brain, CSF, and plasma using high‐powered cohorts. 78”

• cites [78] Shvetcov A, Johnson ECB, Winchester LM, et al. APOE ε4 carriers share immune‐related proteomic changes across neurodegenerative diseases. Nat Med. 2025; 31(8): 2590‐ 2601. 40665049 PMC12353839 sourcePartly supported

  The Discussion reports a pro-inflammatory APOE ε4-associated proteomic signature across brain, CSF and plasma, and Methods > Participants describes a large cohort of 11,270 people. However, the reported cross-tissue finding concerns ε4 carriers, including both heterozygotes and homozygotes; the paper does not establish it specifically for ε4/ε4 individuals across all three tissues. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Exogenous Wnt activation enhances endothelial barrier function.

“Consistently, exogenous Wnt activation enhances endothelial barrier function, 77 suggesting that ApoE3Ch‐EVs may act as modulators of this pathway.”

• cites [77] Laksitorini MD, Yathindranath V, Xiong W, Hombach‐Klonisch S, Miller DW. Modulation of Wnt/β‐catenin signaling promotes blood‐brain barrier phenotype in cultured brain endothelial cells. Sci Rep. 2019; 9(1): 19718. 31873116 PMC6928218 sourceSupported

Classified as probably not a substantial claim.

β-catenin signaling promotes astrocyte reactivity after injury.

“β‐catenin activation was not detected in astrocytes treated with APOE3Ch ‐EVs, which may be beneficial because β‐catenin signaling promotes astrocyte reactivity after injury. 72 , 73”

• cites [72] Yang C, Iyer RR, Yu ACH, et al. β‐Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci. 2012; 109(18): 6963‐ 6968. 22505738 PMC3344971 sourceSupported
• cites [73] Edara VV, Nooka S, Proulx J, Stacy S, Ghorpade A, Borgmann K. β‐catenin regulates wound healing and IL‐6 expression in activated human astrocytes. Biomedicines. 2020; 8(11): 479. 33171974 PMC7694627 sourceSupported

Classified as probably not a substantial claim.

Wnt/β-catenin signaling is a pathway critical for BBB maintenance via regulation of tight junction proteins such as claudin-1.

“These effects may be linked to APOE3Ch cargo, consistent with activation of Wnt/β‐catenin signaling in endothelial cells, 8 a pathway critical for BBB maintenance via regulation of tight junction proteins such as claudin‐1. 65 , 66”

• cites [65] Tran KA, Zhang X, Predescu D, et al. Endothelial β‐catenin signaling is required for maintaining adult blood–brain barrier integrity and central nervous system homeostasis. Circulation. 2016; 133(2): 177‐ 186. 26538583 PMC4814374 sourceSupported
• cites [66] Hussain B, Fang C, Huang X, et al. Endothelial β‐catenin deficiency causes blood‐brain barrier breakdown via enhancing the paracellular and transcellular permeability. Front Mol Neurosci. 2022; 15: 895429. 35615065 PMC9125181 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The EV isolation strategy, based on differential centrifugation, aligns with the 2023 Minimal Information for Studies of Extracellular Vesicles guidelines.

“Our EV isolation strategy, based on differential centrifugation, is cost effective and aligns with the 2023 Minimal Information for Studies of Extracellular Vesicles guidelines, 19 but more specialized platforms (ultracentrifugation, affinity purification, Simoa) may increase analytical sensitivity.”

• cites [19] Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13(2): e12404. 38326288 PMC10850029 sourceSupported

Classified as probably not a substantial claim. May combine two claims.

Wnt/β-catenin signaling supports BBB integrity through junctional stabilization and transcriptional regulation and limits immune infiltration.

“ApoE, identified as an upstream regulator in PSEN1E280A ‐APOE3Ch vesicles, may indicate that vesicular ApoE3Ch modulates intracellular signaling pathways, including the activation of Wnt/β‐catenin signaling, 8 which supports BBB integrity through junctional stabilization and transcriptional regulation 76 and limits immune infiltration. 67”

• cites [8] Perez‐Corredor P, Vanderleest TE, Vacano GN, et al. APOE3 Christchurch modulates β‐catenin/Wnt signaling in iPS cell‐derived cerebral organoids from Alzheimer's cases. Front Mol Neurosci. 2024; 17: 1373568. 38571814 PMC10987717 sourceSupported
• cites [76] Valenta T, Hausmann G, Basler K. The many faces and functions of β‐catenin. EMBO J. 2012; 31(12): 2714‐ 2736. 22617422 PMC3380220 sourcePartly supported

  In “β-Catenin at the membrane: balancing adhesion and signalling” (page unavailable), the paper describes β-catenin’s roles in cell-cell junctions and Wnt-target gene transcription. It does not connect those roles to blood–brain barrier integrity, so the BBB-specific claim is unsupported. The separate claim about immune infiltration carries citation 67, not the citation to this paper. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [67] Lengfeld JE, Lutz SE, Smith JR, et al. Endothelial Wnt/β‐catenin signaling reduces immune cell infiltration in multiple sclerosis. Proc Natl Acad Sci. 2017; 114(7): E1168‐ E1177. 28137846 PMC5320985 sourceSupported

Classified as probably not a substantial claim. May combine two claims.

ApoE has been detected in EVs and proposed as a therapeutic mediator.

“ApoE has been detected in EVs and proposed as a therapeutic mediator, 56 while APOE3Ch is linked to increased homeostatic astrocytes and microglia and reduced disease‐associated populations. 75”

• cites [56] Jiang S, Li X, Li Y, et al. APOE from patient‐derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model. Sci Transl Med. 2025; 16(736): eadg5116. 38416841 sourceSupported

May combine two claims.

APOE3Ch is linked to increased homeostatic astrocytes and microglia and reduced disease-associated populations.

“ApoE has been detected in EVs and proposed as a therapeutic mediator, 56 while APOE3Ch is linked to increased homeostatic astrocytes and microglia and reduced disease‐associated populations. 75”

• cites [75] Nelson MR, Liu P, Agrawal A, et al. The APOE‐R136S mutation protects against APOE4‐driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023; 26(12): 2104‐ 2121. 37957317 PMC10689245 sourcePartly supported

  The Results sections on astrocytes (Fig. 7) and microglia (Fig. 8) report more homeostatic cells and fewer disease-associated cells in tauopathy mice carrying APOE4-R136S. The Main section identifies APOE3-Christchurch as APOE3-R136S, but the reported cell-population findings concern the mutation on an APOE4 background, not APOE3Ch itself. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Cholesterol buildup in neurons and glia promotes stress and inflammation, whereas its removal may reduce lipid burden.

“These may reflect a compensatory mechanism to export excess cholesterol and preserve NVU homeostasis, as cholesterol buildup in neurons and glia promotes stress and inflammation, whereas its removal may reduce lipid burden. 7 , 60”

• cites [7] Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025; 188(1): 187‐ 206.e26. 39532095 PMC11724755 sourceSupported
• cites [60] Gao Y, Ye S, Tang Y, Tong W, Sun S. Brain cholesterol homeostasis and its association with neurodegenerative diseases. Neurochem Int. 2023; 171: 105635. 37949118 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE3Ch iPSC-derived organoids exhibit reduced tau pathology.

“Recent work shows that ApoE3Ch modulates Wnt pathway sensitivity by altering interactions with tau and reducing responsiveness to the Wnt inhibitor DKK1, 61 a mechanism also observed in APOE3Ch iPSC‐derived organoids that exhibit reduced tau pathology. 8”

• cites [8] Perez‐Corredor P, Vanderleest TE, Vacano GN, et al. APOE3 Christchurch modulates β‐catenin/Wnt signaling in iPS cell‐derived cerebral organoids from Alzheimer's cases. Front Mol Neurosci. 2024; 17: 1373568. 38571814 PMC10987717 sourceSupported

May combine two claims.

The percentage of CD171+ EVs was increased in APOE3Ch carriers compared to controls and in PSEN1E280A-APOE3Ch compared to PSEN1E280A-APOE3.

“The percentage of CD171+ EVs was increased in APOE3Ch carriers compared to controls, and likewise, in PSEN1E280A ‐APOE3Ch compared to PSEN1E280A ‐APOE3 (Figure 2A).”

May combine two claims.

In non-MCI PSEN1E280A carriers, PDGFRβ+ and AQP4+ EVs were similar between APOE3 and APOE3Ch, whereas CD171+ EVs were increased in APOE3Ch.

“Consistent with genotypic comparisons, PDGFRβ+ and AQP4+ EVs were similar between groups, whereas CD171+ EVs were increased in APOE3Ch carriers (Figure 2E).”

Probably not a substantial claim: may not pass S3 (load-bearing).

The patient homozygous for APOE3Ch with PSEN1E280A consistently exhibited some of the lowest values within the group.

“Notably, the patient homozygous for APOE3Ch with PSEN1E280A consistently exhibited some of the lowest values within the group.”

May combine two claims.

EVs from APOE3Ch carriers showed lower PDGFRβ levels than controls and reduced AQP4 and CD171 levels, regardless of PSEN1 condition.

“Also, we observed that EVs from APOE3Ch carriers showed lower PDGFRβ levels than controls, and similarly, exhibited reduced AQP4 and CD171 levels, regardless of PSEN1 condition (Figure 2B).”

May combine two claims.

EVs from APOE3Ch carriers showed lower levels of CD45, CD105, and CD235a, and higher levels of CD41a.

“EVs from APOE3Ch carriers also showed lower levels of CD45, CD105, and CD235a, and higher of CD41a (Figure 1F).”

May combine two claims.

FAST scores exhibited positive correlations with CD45 and PDGFRβ abundance, and the percentages of CD105+ EVs and CD45+CD105+ EVs.

“Conversely, FAST scores exhibited positive correlations with CD45 and PDGFRβ abundance, and the percentages of CD105+ EVs and CD45+CD105+ EVs”

May combine two claims.

In non-MCI versus MCI comparison, non-MCI group showed activation of clotting cascade, acute phase response signaling, and serotonin receptor signaling; pathways linked to vascular inflammation, coagulation cascade, and cholesterol metabolism exhibited robust significance.

“In the non‐MCI versus MCI comparison, the non‐MCI group showed activation of the clotting cascade, acute phase response signaling, and serotonin receptor signaling. Pathways linked to vascular inflammation, the coagulation cascade, and cholesterol metabolism exhibited robust significance.”

May combine two claims.

In MCI versus non-MCI PSEN1E280A-APOE3, uncorrected analysis identified increases in LBP, VWF, LPA, GPLD1, F13A1, APOB, TTR, CNDP1, and APCS; after FDR correction, most remained significant except LPA, SERPINA4, and APCS.

“In the MCI versus non‐MCI PSEN1E280A‐APOE3 comparison, the uncorrected analysis identified increases in LBP, VWF, lipoprotein A [LPA], GPLD1, coagulation factor XIII A chain [F13A1], APOB, transthyretin [TTR], CNDP1, and APCS. After FDR correction, most remained significant except LPA, SERPINA4, and APCS (Figure 5D, Table S7A,B).”

May combine two claims.

In non-MCI PSEN1E280A carriers, percentages of apoE+, BODIPY+, and CD171+/BODIPY+ double-positive EVs and apoE and BODIPY abundances were increased in APOE3Ch compared to APOE3.

“The percentages of apoE+, BODIPY+, and CD171+/BODIPY+ double‐positive EVs and the apoE and BODIPY abundances were increased in PSEN1E280A ‐APOE3Ch carriers compared to non‐MCI PSEN1E280A ‐APOE3 carriers (Figure 3E).”

May combine two claims.

In non-MCI PSEN1E280A-APOE3Ch versus APOE3, 23 uncorrected DEPs showed reduced abundance in APOE3Ch-EVs, including VWF, LBP, GPLD1, APOB, CNDP1, F13B, SERPIND1, LPA, and ECM1; FDR correction retained 12 significantly decreased proteins.

“In the non‐MCI PSEN1E280A‐APOE3Ch versus APOE3 comparison, 23 uncorrected DEPs showed reduced abundance in APOE3Ch ‐EVs, including VWF, LBP, GPLD1, APOB, CNDP1, F13B, SERPIND1, LPA, and extracellular matrix protein 1 (ECM1), while FDR correction retained 12 significantly decreased proteins.”

May combine two claims.

IPA analysis revealed that non-MCI PSEN1E280A-APOE3 versus MCI PSEN1E280A-APOE3 showed predicted activation of IL-6, linked to at least three DEPs involved in inflammation and lipid metabolism.

“IPA analysis revealed that non‐MCI PSEN1E280A‐APOE3 versus MCI PSEN1E280A‐APOE3 showed predicted activation of IL‐6, linked to at least three DEPs involved in inflammation and lipid metabolism”

May combine two claims.

IPA predicted coagulation activation in PSEN1E280A-APOE3 but inhibition in PSEN1E280A-APOE3Ch.

“In our study, non‐MCI PSEN1E280A‐APOE3Ch carriers showed increased CD41a+ EVs, while IPA predicted coagulation activation in PSEN1E280A‐APOE3 but inhibition in PSEN1E280A‐APOE3Ch .”

May combine two claims.

PSEN1E280A-APOE3Ch EVs preserved endothelial integrity and attenuated astrocytic responses.

“In contrast, PSEN1E280A ‐APOE3Ch EVs displayed reduced vascular and leukocyte markers, but were enriched in apoE and neutral lipids, with proteomic signatures opposite to PSEN1E280A ‐APOE3 EVs, preserving endothelial integrity and attenuating astrocytic responses.”

Probably not a substantial claim: may not pass S3 (load-bearing).

189 proteins common to all groups were identified by LC-MS/MS.

“We compare EV cargo profiles using liquid chromatography tandem mass spectrometry and identified 189 proteins common to all groups (Figure S4A, Table S4 in supporting information)”

May combine two claims.

EVs reflect inflammation, vascular dysfunction, and lipid metabolism changes before MCI.

“While studied mainly for carrying phosphorylated tau and propagating pathology, 21 , 22 , 44 our findings show that EVs also reflect inflammation, vascular dysfunction, and lipid metabolism changes before MCI, supporting their utility as early biomarkers of disease resistance or progression, particularly because EV markers including CD45, CD105, and PDGFRβ correlate with cognitive performance.”

May combine two claims.

PLS-DA revealed distinct clustering among study groups, with component 1 accounting for 62.2% of variance; APOE3Ch-EVs formed clusters near each other, MCI PSEN1E280A-APOE3 clustered closer to CNT, and non-MCI PSEN1E280A-APOE3 were clearly separated from all other groups.

“The PLS‐DA analysis revealed distinct clustering among the study groups, with component 1 accounting for 62.2% of the variance. APOE3Ch ‐EVs formed clusters near each other, while MCI PSEN1E280A ‐APOE3 clustered closer to CNT. In contrast, non‐MCI PSEN1E280A ‐APOE3 carriers were clearly separated from all other groups”

May combine two claims.

In non-MCI PSEN1E280A-APOE3Ch, IL-6 was predicted to be inhibited, resulting in reduced cell migration and acute-phase response signaling, and decreased activation of LXR/RXR pathway.

“In non‐MCI PSEN1E280A ‐APOE3Ch , IL‐6 was predicted to be inhibited, resulting in reduced cell migration and acute‐phase response signaling, as well as decreased activation of the liver X receptor/retinoid X receptor (LXR/RXR) pathway (Figure 6B).”

May combine two claims.

Both wild-type ApoE3 and ApoE3Ch reduced VEGF-induced vascular permeability and helped preserve TEER.

“Both wild‐type ApoE3 and ApoE3Ch reduced VEGF‐induced vascular permeability and helped preserve TEER (Figure 7D).”

May combine two claims.

MMSE scores showed negative correlations with CD105 and PDGFRβ levels in EVs, and with the percentage of CD45+CD105+ EVs.

“MMSE scores showed negative correlations with both CD105 and PDGFRβ levels in EVs, as well as with the percentage of CD45+CD105+ EVs”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Of the 189 common proteins, 127 were previously reported in both Vesiclepedia and ExoCarta, 16 were unique to Vesiclepedia, 7 were exclusive to ExoCarta, and the remaining were not listed in either database.

“Of these 189 proteins, 127 were previously reported in both the Vesiclepedia and ExoCarta databases, 16 were unique to Vesiclepedia, 7 were exclusive to ExoCarta, and the remaining proteins were not listed in either database (Figure S4B).”

May combine two claims.

Plasma analyses showed higher LDL, VLDL, total cholesterol, and triglycerides in non-MCI PSEN1E280A-APOE3Ch carriers.

“Plasma analyses showed higher LDL, VLDL, total cholesterol, and triglycerides in non‐MCI PSEN1E280A‐APOE3Ch carriers (Figure S2A)”

May combine two claims.

ApoE3Ch promoted nuclear localization of β-catenin, whereas ApoE4 led to cytosolic displacement of β-catenin and disruption of endothelial junctions.

“Furthermore, ApoE3Ch promoted nuclear localization of β‐catenin, in contrast to ApoE4, which led to cytosolic displacement of β‐catenin and disruption of endothelial junctions.”

May combine two claims.

In non-MCI PSEN1E280A-APOE3 versus CNT, uncorrected analysis revealed increased inflammatory and vascular proteins (APCS, VWF, GPLD1, CNDP1, APOB, FN1, IGHV3-64D), none of which remained significant after FDR correction.

“In the non‐MCI PSEN1E280A‐APOE3 versus CNT comparison, the uncorrected analysis revealed increased inflammatory and vascular proteins (APCS, Von Willebrand factor [VWF], glycosylphosphatidylinositol specific phospholipase D1 [GPLD1], CNDP1, APOB, fibronectin 1 [FN1], IGHV3‐64D), none of which remained significant after FDR correction (Table S7A,B in supporting information).”

Probably not a substantial claim: may not pass S3 (load-bearing).

EV exposure induced average cytotoxicity of 11% to 23% across groups.

“EV exposure induced average cytotoxicity of 11% to 23% across groups (Figure S4B).”

May combine two claims.

EVs from PSEN1E280A-APOE3Ch carriers preserved endothelial integrity and reduced astrocytic activation in co-culture.

“EVs from PSEN1E280A‐APOE3Ch carriers preserved endothelial integrity and reduced astrocytic activation in co‐culture.”

May combine two claims.

ApoE3Ch enhances β-catenin nuclear translocation and restores adherens junction integrity disrupted by ApoE4.

“On the right, quantification of nuclear β‐catenin demonstrates that ApoE3Ch enhances β‐catenin nuclear translocation and restores adherens junction integrity disrupted by ApoE4.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Participants were excluded if they were pregnant, had active infectious symptoms, had autoimmune or inflammatory disorders, or reported consumption of psychoactive substances.

“Participants were excluded if they were pregnant, had active infectious symptoms, had autoimmune or inflammatory disorders, or reported consumption of psychoactive substances.”

May combine two claims.

These biomarkers mainly reflect downstream pathology and provide limited insight into upstream mechanisms driving disease onset and progression.

“However, these biomarkers mainly reflect downstream pathology and provide limited insight into upstream mechanisms driving disease onset and progression.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

ADAD results from mutations in the amyloid precursor protein (APP) gene or in the presenilin genes PSEN1 and PSEN2, which are critical for APP processing.

“ADAD results from mutations in the amyloid precursor protein (APP) gene or in the presenilin genes PSEN1 and PSEN2, which are critical for APP processing. 2”

• cites [2] Piaceri I, Nacmias B, Sorbi S. Genetics of familial and sporadic Alzheimer's disease. Front Biosci Elite. 2013; 5(1): 167‐ 177. 23276979 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The reported n refers to individual patients; the number of samples analyzed may vary slightly across experiments due to limited sample availability.

“The reported n refers to individual patients. This information corresponds to the initial sample sizes; however, the number of samples analyzed may vary slightly across experiments due to limited sample availability.”

May combine two claims.

These findings offer mechanistic insight into APOE3Ch-associated resilience and highlight EVs as sensitive indicators of early disease processes.

“These findings offer mechanistic insight into APOE3Ch ‐associated resilience and highlight EVs as sensitive indicators of early disease processes.”

• AssumptionRests on an assumption: Plasma EV cargo reflects brain/NVU pathological processes in ADAD, such that peripheral EV profiles can serve as indicators of early brain changes.
• AssumptionRests on an assumption: The APOE3Ch-associated EV phenotype mediates the clinical protection against ADAD.

Probably not a substantial claim: may not pass S3 (load-bearing).

All participants gave written informed consent.

“The study was approved by the University of Antioquia's review boards (Record No. 119 dated August 14, 2018‐ Sede de Investigación Universitaria, Universidad de Antioquia), and all participants gave written informed consent.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Groups were matched for sex and age, except for the MCI group, whose participants were required to be older to reflect the typical age of onset for MCI.

“Groups were matched for sex and age, except for the MCI group, whose participants were required to be older to reflect the typical age of onset for MCI.”

• AssumptionRests on an assumption: The MCI group being older than other groups does not confound EV comparisons.

Classified as probably not a substantial claim.

These NVU-EV changes could reflect early APOE- and cognition-related shifts in neurovascular coupling.

“These NVU‐EV changes could reflect early APOE‐ and cognition‐related shifts in neurovascular coupling.”

Probably not a substantial claim: may not pass S3 (load-bearing).

These patterns may reflect subtle molecular alterations present in these cell types prior to the onset of clinical impairment.

“These patterns may reflect subtle molecular alterations present in these cell types prior to the onset of clinical impairment.”

May combine two claims.

These findings highlight APOE3Ch-EVs as modulators of vascular and inflammatory pathways with biomarker and therapeutic potential in ADAD.

“These findings highlight APOE3Ch ‐EVs as modulators of vascular and inflammatory pathways with biomarker and therapeutic potential in ADAD.”

• AssumptionRests on an assumption: Plasma EV cargo reflects brain/NVU pathological processes in ADAD, such that peripheral EV profiles can serve as indicators of early brain changes.
• AssumptionRests on an assumption: The APOE3Ch-associated EV phenotype mediates the clinical protection against ADAD.

May combine two claims.

APOE3Ch is associated with increased CD171+ EVs and reduced astrocytic and pericytes cell markers in peripheral EVs, even in PSEN1E280A carriers.

“Overall, APOE3Ch is associated with increased CD171+ EVs and reduced astrocytic and pericytes cell markers in peripheral EVs, even in PSEN1E280A carriers.”

• AssumptionRests on an assumption: The cell-type markers used in flow cytometry specifically identify the indicated cell types.

Probably not a substantial claim: may not pass S3 (load-bearing).

In the peripheral circulation, EVs and lipoproteins are the predominant nanoparticle populations.

“In the peripheral circulation, extracellular vesicles (EVs) and lipoproteins are the predominant nanoparticle populations. 18”

• cites [18] Nguyen PHD, Le AH, Pek JSQ, et al. Extracellular vesicles and lipoproteins – Smart messengers of blood cells in the circulation. J Extracell Biol. 2022; 1(7): e49. 38938581 PMC11080875 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

The isolated material contains both small and large EVs, with similar size and concentration across all groups.

“In accordance with Minimal Information for Studies of Extracellular Vesicles 2023 guidelines, we verified that the isolated material contains both small and large EVs, with similar size and concentration across all groups (Figure S1).”

Probably not a substantial claim: may not pass S3 (load-bearing).

The study was approved by the University of Antioquia's review boards (Record No. 119 dated August 14, 2018).

“The study was approved by the University of Antioquia's review boards (Record No. 119 dated August 14, 2018‐ Sede de Investigación Universitaria, Universidad de Antioquia), and all participants gave written informed consent.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The Paisa kindred in Colombia harbors PSEN1E280A and is the largest known family affected by ADAD due to PSEN1E280A.

“The Paisa kindred in Colombia, which harbors this mutation, is the largest known family affected by ADAD due to PSEN1E280A . 4”

• cites [4] Acosta‐Baena N, Sepulveda‐Falla D, Lopera‐Gómez CM, et al. Pre‐dementia clinical stages in presenilin 1 E280A familial early‐onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 2011; 10(3): 213‐ 220. 21296022 sourceNot checked — no full text of the source

May combine two claims.

PSEN1E280A-APOE3 EVs exhibit elevated levels of endothelial and leukocyte markers before MCI, while PSEN1E280A-APOE3Ch carriers show reduced levels of these markers but increased abundance of a platelet-associated marker, indicating a shift in the profile of systemic EVs.

“These findings suggest that PSEN1E280A ‐APOE3 EVs exhibit elevated levels of endothelial and leukocytes markers before the MCI, while PSEN1E280A ‐APOE3Ch carriers show reduced levels of these markers but increased abundance of a platelet‐associated marker, indicating a shift in the profile of systemic EVs.”

• AssumptionRests on an assumption: The cell-type markers used in flow cytometry specifically identify the indicated cell types.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Comorbidities exhibited a mild age-related trend, with no detectable dependence on APOE or PSEN1 genotype.

“Comorbidities exhibited a mild age‐related trend, with no detectable dependence on APOE or PSEN1 genotype.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Experimental procedures were performed under blinded conditions: for PSEN1E280A carriers, the experimenter was unaware of the cognitive status of participants (MCI vs. non-MCI), and for APOE3Ch carriers, the PSEN1E280A genotype was blinded.

“Experimental procedures were performed under blinded conditions: for PSEN1E280A carriers, the experimenter was unaware of the cognitive status of participants (MCI vs. non‐MCI), and for APOE3Ch carriers, the PSEN1E280A genotype was blinded.”

Classified as probably not a substantial claim. May combine two claims.

FDR correction reduced detectable DEPs; adjusted values are used as primary results, and unadjusted values are reported as exploratory.

“As expected, FDR correction reduced detectable DEPs; therefore, adjusted values are used as primary results, and unadjusted values are reported as exploratory.”

May combine two claims.

This shift suggests a potential dampening of pathogenic inflammation signaling in APOE3Ch carriers, consistent with their observed clinical resilience and vascular protection.

“This shift suggests a potential dampening of pathogenic inflammation signaling in APOE3Ch carriers, consistent with their observed clinical resilience and vascular protection.”

• AssumptionRests on an assumption: APOE3Ch carriers exhibit clinical resilience and vascular protection.

May combine two claims.

Several observed correlations were influenced by a single outlier sample; after excluding it, only the association between MMSE and MFI-CD105 persists.

“It is important to acknowledge that several of the observed correlations were influenced by a single outlier sample. When this sample is excluded from the analysis, the only cognition‐related association that persists is between MMSE and MFI‐CD105 (Table S3 in supporting information).”

May combine two claims.

APOE3Ch-EV treatment enhances cellular uptake or accumulation of apoE.

“While it is not possible to determine the exact proportion of intracellular apoE that is EV‐derived versus endogenous, both endothelial and astrocytic cells treated with APOE3Ch ‐EVs tended to exhibit a higher number of intracellular apoE‐positive clusters compared to those treated with EVs from APOE3 carriers (Figures 8E,F, S5G and S5H), suggesting enhanced cellular uptake or accumulation of apoE”

Probably not a substantial claim: may not pass S3 (load-bearing).

This profile may reflect an altered platelet state favoring vesicle-mediated communication over thrombosis.

“Given that platelet EVs can also carry regulatory and pro‐neurogenic factors, 50 , 51 , 52 this profile may reflect an altered platelet state favoring vesicle‐mediated communication over thrombosis.”

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE variants contribute to lipid disorders.

“APOE variants contribute to lipid disorders 58 ; like APOE2, APOE3Ch may promote hyperlipidemia due to reduced receptor binding but also limit uptake of oxidized lipoproteins, protecting against lipid overload and oxidative stress. 7”

• cites [58] Bea AM, Larrea‐Sebal A, Marco‐Benedi V, et al. Contribution of APOE genetic variants to dyslipidemia. Arterioscler Thromb Vasc Biol. 2023; 43(6): 1066‐ 1077. 37051929 sourceNot checked — no full text of the source

May combine two claims.

Based on EV composition, APOE3Ch may modulate vascular signaling by repressing pro-inflammatory and pro-migratory pathways while promoting molecular changes that reduce endothelial activation and adhesion.

“These findings suggest that, based on EV composition, APOE3Ch may modulate vascular signaling by repressing pro‐inflammatory and pro‐migratory pathways while promoting molecular changes that reduce endothelial activation and adhesion.”

May combine two claims.

These DEP signatures show early vascular-inflammatory activation in PSEN1E280A-APOE3 carriers, whereas APOE3Ch-EVs display the opposite pattern, supporting a distinct protective molecular profile.

“Overall, these DEP signatures show early vascular‐inflammatory activation in PSEN1E280A‐APOE3 carriers, whereas APOE3Ch ‐EVs display the opposite pattern, supporting a distinct protective molecular profile.”

Probably not a substantial claim: may not pass S3 (load-bearing).

These three proteins support roles in immunomodulatory or homeostatic functions.

“supporting roles in immunomodulatory or homeostatic functions (Figure 5E, Table S7A,B).”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The difference in apoE abundance was consistently detected across multiple samples by flow cytometry, though not clearly observed in Western blot due to inclusion of only one representative patient per group.

“Although this difference is not clearly observed in the Western blot due to the inclusion of only one representative patient per group (Figure 3F), it was consistently detected across multiple samples by flow cytometry.”

May combine two claims.

These findings confirm the extracellular and vesicular origin of the protein cargo, consistent with a profile enriched in EVs.

“These findings confirm the extracellular and vesicular origin of the protein cargo, consistent with a profile enriched in EVs.”

Probably not a substantial claim: may not pass S3 (load-bearing).

These pathways are processes implicated in vascular inflammation, coagulopathy, and neurodegeneration.

“all of which are processes implicated in vascular inflammation, coagulopathy, and neurodegeneration.”

May combine two claims.

This implies reduced neutral-lipid content in EVs alongside heightened vascular-inflammatory activity.

“implying reduced neutral‐lipid content in EVs alongside heightened vascular‐inflammatory activity (Figure S3A,C).”

May combine two claims.

PSEN1E280A-APOE3Ch EVs may promote endothelial integrity and astrocytic homeostasis, potentially through modulation of β-catenin signaling.

“These findings suggest that PSEN1E280A‐APOE3Ch , unlike PSEN1E280A ‐APOE3‐EVs, may promote endothelial integrity and astrocytic homeostasis, potentially through modulation of β‐catenin signaling.”

May combine two claims.

These effects may be linked to APOE3Ch cargo, consistent with activation of Wnt/β-catenin signaling in endothelial cells.

“These effects may be linked to APOE3Ch cargo, consistent with activation of Wnt/β‐catenin signaling in endothelial cells, 8 a pathway critical for BBB maintenance via regulation of tight junction proteins such as claudin‐1. 65 , 66”

Probably not a substantial claim: may not pass S3 (load-bearing).

Vesicular ApoE3Ch may modulate intracellular signaling pathways, including activation of Wnt/β-catenin signaling.

“ApoE, identified as an upstream regulator in PSEN1E280A ‐APOE3Ch vesicles, may indicate that vesicular ApoE3Ch modulates intracellular signaling pathways, including the activation of Wnt/β‐catenin signaling, 8 which supports BBB integrity through junctional stabilization and transcriptional regulation 76 and limits immune infiltration. 67”

Probably not a substantial claim: may not pass S3 (load-bearing).

The modest increase in lipid cargo in APOE3Ch-EVs may reflect a regulated lipid-export mechanism.

“Additionally, the modest increase in lipid cargo in APOE3Ch ‐EVs may reflect a regulated lipid‐export mechanism.”

May combine two claims.

This suggests dampened astrocytic responses, possibly influenced by differential apoE uptake.

“Consistently, APOE3Ch ‐EVs reduced GFAP expression, suggesting dampened astrocytic responses, possibly influenced by differential apoE uptake. 74”

Probably not a substantial claim: may not pass S3 (load-bearing).

ID3 enhances β-catenin transcriptional activity by blocking E47-mediated repression.

“Proteomic and IPA analyses also identified ID3, which enhances β‐catenin transcriptional activity by blocking E47‐mediated repression. 70 , 71”

• cites [70] Zhang L, Shi S, Zhang J, Zhou F, ten Dijke P. Wnt/β‐catenin signaling changes C2C12 myoblast proliferation and differentiation by inducing Id3 expression. Biochem Biophys Res Commun. 2012; 419(1): 83‐ 88. 22326917 sourceNot checked — no full text of the source
• cites [71] Huang L, Cai J, Guo H, et al. ID3 promotes stem cell features and predicts chemotherapeutic response of intrahepatic cholangiocarcinoma. Hepatology. 2019; 69(5): 1995‐ 2012. 30520117 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

LEF-1 cooperizes with stabilized β-catenin to activate Wnt target genes.

“Supporting this, lymphoid enhancer‐binding factor‐1 was upregulated in endothelial cells, where it cooperizes with stabilized β‐catenin to activate Wnt target genes. 69”

• cites [69] Behrens J, von Kries JP, Kühl M, et al. Functional interaction of β‐catenin with the transcription factor LEF‐1. Nature. 1996; 382(6592): 638‐ 642. 8757136 sourceNot checked — no full text of the source

May combine two claims.

Sample sizes (n = 9-10 per group) are appropriate for detecting the large effect sizes observed in EV and proteomic signatures, but more subtle differences may remain underpowered.

“Although our sample sizes (n = 9–10 per group) are appropriate for detecting the large effect sizes observed in EV and proteomic signatures, more subtle differences may remain underpowered and should be interpreted with caution.”